Team:UCSF

From 2010.igem.org

(Difference between revisions)
(Project Description)
(Project Description)
 
(178 intermediate revisions not shown)
Line 1: Line 1:
-
[[Image:Thecave.JPG|905px|center|The Cave: The Hub of UCSF's iGEM team]]
 
-
 
-
{| style="color:#6d98ab;background-color:#6d98ab;" cellpadding="3" cellspacing="2" border="1" bordercolor="#fff" width="94%" align="center"
 
-
!align="center"|[[Team:UCSF|Home]]
 
-
!align="center"|[[Team:UCSF/Team|Team]]
 
-
!align="center"|[http://igem.org/Team.cgi?year=2010&team_name=UCSF Official Team Profile]
 
-
!align="center"|[[Team:UCSF/Project|Project]]
 
-
!align="center"|[[Team:UCSF/Parts|Parts Submitted to the Registry]]
 
-
!align="center"|[[Team:UCSF/Modeling|Modeling]]
 
-
!align="center"|[[Team:UCSF/Notebook|Notebook]]
 
-
!align="center"|[[Team:UCSF/Safety|Safety]]
 
-
|}
 
-
 
<html>
<html>
 +
<script>
 +
var Numbering="N1";
 +
</script>
 +
</html>
 +
{{Template:UCSF/BannerAndNav}}
 +
{{Template:UCSF/LeftStart}}
<br>
<br>
-
<div style="text-align:center;  font-size: large; color: #0099CC"><b> Work In Progress </b></div>
+
===Project Description===
-
<br>
+
-
<br>
+
-
</html>
+
-
=='''Project Description'''==
+
Killer cells of the immune system identify cancer and pathogen-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, killer cells use a variety of receptors, which bind to specific ligands on the target cells’ surface. If the target cell is deemed potentially dangerous, the killer cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the killer cell releases cytotoxic granules to kill the target cell without harming nearby cells, triggering a directed apoptotic response.
-
Natural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death.
+
Our team will focus on improving killer cells’ specificity and killing efficiency towards cancerous target cells. By using tools of synthetic biology, we hope to create powerful killing bio-machines to fight cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
-
Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
+
<br>
-
<!-- *** What falls between these lines is the Alert Box!  You can remove it from your pages once you have read and understood the alert *** -- display: none>
+
<html>
 +
<a href="http://2010.igem.org/Team:UCSF/Project/Precision"><img src="http://2010.igem.org/wiki/images/2/28/UCSF_precision_home_icon.png" width="208" border="0" alt="Greater Precision" />
 +
</a>
 +
<a href="http://2010.igem.org/Team:UCSF/Project/Signaling"><img src="http://2010.igem.org/wiki/images/9/9a/UCSF_signaling_home_icon.png" width="208" border="0" alt="Stronger Signaling" />
 +
</a>
 +
<a href="http://2010.igem.org/Team:UCSF/Project/Arsenal" ><img src="http://2010.igem.org/wiki/images/3/35/UCSF_arsenal_home_icon.png" border="0" width="208" alt="Better Arsenal" />
 +
</a>
 +
<br><br>
 +
</html>
 +
{{Template:UCSF/LeftEnd}}
 +
{{Template:UCSF/RightStart}}
<html>
<html>
-
<div id="box" style="width: 700px; margin-left: 137px; padding: 5px; border: 3px solid #000; background-color: #fe2b33;">
+
<br><br>
-
<div id="template" style="text-align: center; font-weight: bold; font-size: large; color: #f6f6f6; padding: 5px;">
+
<h3 style="color:black;">TEAM</h3>
-
This is a template page. READ THESE INSTRUCTIONS.
+
<div align="center">
-
</div>
+
<a href="http://2010.igem.org/Team:UCSF/Team"><img src="http://2010.igem.org/wiki/images/f/ff/Team_photo.png" /></a>
-
<div id="instructions" style="text-align: center; font-weight: normal; font-size: small; color: #f6f6f6; padding: 5px;">
+
-
You are provided with this team page template with which to start the iGEM season.  You may choose to personalize it to fit your team but keep the same "look." Or you may choose to take your team wiki to a different level and design your own wiki.  You can find some examples <a href="http://2009.igem.org/Help:Template/Examples">HERE</a>.
+
-
</div>
+
-
<div id="warning" style="text-align: center; font-weight: bold; font-size: small; color: #f6f6f6; padding: 5px;">
+
-
You <strong>MUST</strong> have a team description page, a project abstract, a complete project description, a lab notebook, and a safety page.  PLEASE keep all of your pages within your teams namespace. 
+
</div>
</div>
 +
<br><br>
 +
 +
<h3 style="color:black;">SPONSORS</h3>
 +
<div align="center">
 +
<a href="http://2010.igem.org/Team:UCSF/Sponsors"><img src="http://2010.igem.org/wiki/images/3/38/Sponsors_2010.png" width="200px" /></a>
</div>
</div>
 +
 +
<br><br>
 +
<h5 style="color:black;">Follow us on <a href="http://twitter.com/#!/iGEM_UCSF">Twitter!</a></h5>
</html>
</html>
-
<!-- *** End of the alert box *** -->
 
-
<!-- *** Original wiki *** -- display:none>
+
 
-
{|align="justify"
+
{{Template:UCSF/RightEnd}}
-
|You can write a background of your team here.  Give us a background of your team, the members, etc.  Or tell us more about something of your choosing.
+
-
|[[Image:UCSF_logo.png|200px|right|frame]]
+
-
|-
+
-
|
+
-
''Tell us more about your project.  Give us background.  Use this as the abstract of your project.  Be descriptive but concise (1-2 paragraphs)''
+
-
|[[Image:UCSF_team.png|right|frame|Your team picture]]
+
-
|-
+
-
|
+
-
|align="center"|[[Team:UCSF | Team Example]]
+
-
|}
+
-
</div>
+
__NOTOC__
__NOTOC__
-
 
-
 
-
 
-
<a href="http://www2.clustrmaps.com/counter/maps.php?url=http://2010.igem.org/Team:UCSF" id="clustrMapsLink"><img src="http://www2.clustrmaps.com/counter/index2.php?url=http://2010.igem.org/Team:UCSF" style="border:0px;" alt="Locations of visitors to this page" title="Locations of visitors to this page" id="clustrMapsImg" onerror="this.onerror=null; this.src='http://clustrmaps.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com';" />
 
-
</a>
 

Latest revision as of 22:27, 15 November 2010


Project Description

Killer cells of the immune system identify cancer and pathogen-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, killer cells use a variety of receptors, which bind to specific ligands on the target cells’ surface. If the target cell is deemed potentially dangerous, the killer cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the killer cell releases cytotoxic granules to kill the target cell without harming nearby cells, triggering a directed apoptotic response.

Our team will focus on improving killer cells’ specificity and killing efficiency towards cancerous target cells. By using tools of synthetic biology, we hope to create powerful killing bio-machines to fight cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.


Greater Precision Stronger Signaling Better Arsenal